Grade

When a pathologist examines cancer cells under a microscope, one of the key questions is how abnormal those cells look compared to the normal tissue they came from. This assessment is called grading, and it provides important information about a tumor's likely behavior. Well-differentiated, or low-grade, cells still retain many of the characteristics of their tissue of origin — they look recognizable and tend to divide relatively slowly. Poorly differentiated, or high-grade, cells have lost most of those features — they look chaotic and disorganized and tend to grow and spread more rapidly.

For breast cancer, the most widely used system is the Nottingham grading system (also called the Scarff-Bloom-Richardson system), which evaluates three characteristics: how much of the tumor forms glandular structures (tubule formation), how irregular the nuclei of the cancer cells are (nuclear pleomorphism), and how actively the cells are dividing (mitotic rate). Each feature is scored 1 to 3, and the scores are added together to produce an overall grade of 1 (low grade), 2 (intermediate grade), or 3 (high grade).

Grade is one of several factors — along with stage, hormone receptor status, HER2 status, and others — that pathologists and oncologists use together to build a complete picture of a cancer and guide treatment planning. A grade 1 tumor that is small and localized may be managed very differently from a grade 3 tumor of similar size, because their likely behavior and responsiveness to treatment can differ substantially.

Grade is part of the language of cancer pathology reports, and understanding what it means can help you make sense of what your doctors are telling you about your diagnosis. If your report says grade 1 or well-differentiated, that generally indicates a slower-growing cancer that is likely to respond well to hormone therapy and is less likely to require aggressive chemotherapy. Grade 3 or poorly differentiated suggests faster growth and may indicate that more aggressive treatment is appropriate.

It is important to remember that grade is not destiny — it is one data point among many. A high-grade tumor caught at an early stage often has an excellent prognosis. A low-grade tumor, though slow-growing, still needs treatment and follow-up. Asking your oncologist how grade fits into the overall picture of your diagnosis — alongside stage, receptor status, and any genomic testing results — will give you a much fuller understanding of your specific situation and the reasoning behind your treatment plan.